DrugPatentWatch Database Preview
Safinamide mesylate - Generic Drug Details
What are the generic sources for safinamide mesylate and what is the scope of freedom to operate?
Safinamide mesylate
is the generic ingredient in one branded drug marketed by Us Worldmeds Llc and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.Safinamide mesylate has ninety-seven patent family members in thirty-one countries.
There are two drug master file entries for safinamide mesylate.
Summary for safinamide mesylate
| International Patents: | 97 |
| US Patents: | 3 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Master File Entries: | 2 |
| Bulk Api Vendors: | 55 |
| Patent Applications: | 24 |
| DailyMed Link: | safinamide mesylate at DailyMed |
Synonyms for safinamide mesylate
| (S)-( )-2-(4-(3-Fluorobenzyloxy) benzylamino)propanamide, methanesulfonate |
| (S)-2-((4-((3-Fluorobenzyl)oxy)benzyl)-amino)propanamide methanesulfonate |
| (S)-2-((4-((3-Fluorobenzyl)oxy)benzyl)amino)propanamide methanesulfonate |
| (S)-2-((4-((3-fluorobenzyl)oxy)benzyl)amino)propanamidemethanesulfonate |
| (S)-2-[[4-[(3-fluorobenzyl)oxy]benzyl]amino]propanamide methanesulfonate |
| (S)-2-[4-(3-Fluorobenzyloxy)benzylamino]propanamide methanesulfonate |
| (S)-2[4-(3-fluorobenzyloxy)benzylamino]propanamide methanesulfonate |
| 0395AB |
| 202825-46-5 |
| AC-27739 |
| AKOS015902297 |
| ANW-58665 |
| API0007783 |
| BCP16018 |
| CHEMBL48582 |
| CTK8B7807 |
| D10191 |
| EMD 1195686 mesylate |
| EMD-1195686 |
| EX-A2640 |
| FCE-28073 |
| FCE-28073, PNU-151774E, NW-1015, 202825-46-5 |
| FCE-28073(R-isomer) |
| FT-0697967 |
| J-013174 |
| KS-000002KO |
| MLS006010740 |
| NW 1015 |
| NW-1015 |
| PNU 151774E |
| PNU-151774E |
| PNU-151774E,FCE28073 |
| Propanamide, 2-(((4-((3-fluorophenyl)methoxy)phenyl)methyl)amino)-, (S)-, monomethanesulfonate |
| Propanamide, 2-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]-, (2S)-, methanesulfonate (1:1) |
| Q27294690 |
| R-isomer |
| s1472 |
| Safinamide mesilate |
| Safinamide mesilate (JAN) |
| Safinamide Mesylate (FCE28073) |
| Safinamide mesylate (USAN) |
| Safinamide mesylate [USAN] |
| Safinamide mesylate salt |
| Safinamide mesylate salt, >=98% (HPLC) |
| safinamide methanesulfonate |
| SB16692 |
| SC-96756 |
| SCHEMBL1665715 |
| SMR004701699 |
| ST24035821 |
| SW219452-1 |
| TC-147410 |
| UNII-YS90V3DTX0 |
| Xadago (TN) |
| YKOCHIUQOBQIAC-YDALLXLXSA-N |
| YS90V3DTX0 |
| Z-3267 |
US Patents and Regulatory Information for safinamide mesylate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Us Worldmeds Llc | XADAGO | safinamide mesylate | TABLET;ORAL | 207145-001 | Mar 21, 2017 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Us Worldmeds Llc | XADAGO | safinamide mesylate | TABLET;ORAL | 207145-002 | Mar 21, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Us Worldmeds Llc | XADAGO | safinamide mesylate | TABLET;ORAL | 207145-002 | Mar 21, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Us Worldmeds Llc | XADAGO | safinamide mesylate | TABLET;ORAL | 207145-001 | Mar 21, 2017 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for safinamide mesylate
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Cyprus | 1118113 | Start Trial |
| Japan | 2009541232 | Start Trial |
| Taiwan | I340640 | Start Trial |
| Eurasian Patent Organization | 200970028 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for safinamide mesylate
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1613296 | 132016000023012 | Italy | Start Trial | PRODUCT NAME: SAFINAMIDE(XADAGO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/14/984, 20150224 |
| 1613296 | C20150033 00258 | Estonia | Start Trial | PRODUCT NAME: SAFINAMIID;REG NO/DATE: EU/1/14/984 26.02.2015 |
| 1613296 | CA 2015 00042 | Denmark | Start Trial | PRODUCT NAME: KOMBINATION AF SAFINAMID OG LEVOPODA/PDI; REG. NO/DATE: EU/1/14/984/001-010 20150224 |
| 1613296 | 122015000058 | Germany | Start Trial | PRODUCT NAME: XADAGO; REGISTRATION NO/DATE: EU/1/14/984 20150224 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
